Madrigal Pharmaceuticals Announces Director, Officer, and Compensation Changes
Ticker: MDGL · Form: 8-K · Filed: Dec 11, 2025 · CIK: 1157601
Sentiment: neutral
Topics: corporate-governance, officer-changes, director-changes
Related Tickers: MDGL
TL;DR
Madrigal Pharma (MDGL) board shakeup and exec comp changes announced Dec 5.
AI Summary
Madrigal Pharmaceuticals, Inc. announced on December 5, 2025, changes related to its board of directors and executive compensation. Specifically, the company reported the departure of a director and adjustments to compensatory arrangements for certain officers. The filing also includes information on the election of new directors and the appointment of certain officers.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — The filing reports routine corporate governance changes and does not indicate any significant financial distress or operational disruption.
Key Numbers
- 001-33277 — SEC File Number (Identifies the company's filing history with the SEC.)
- 04-3508648 — IRS Employer Identification No. (Tax identification number for the company.)
Key Players & Entities
- MADRIGAL PHARMACEUTICALS, INC. (company) — Registrant
- December 5, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Four Tower Bridge 200 Barr Harbor Drive, Suite 200 West Conshohocken, Pennsylvania 19428 (address) — Principal executive offices
- SYNTA PHARMACEUTICALS CORP (company) — Former company name
FAQ
Who departed from the board of directors?
The filing indicates the departure of a director, but the specific name is not provided in the provided text.
What is the exact date of the reported event?
The date of the earliest event reported is December 5, 2025.
What is the principal executive office address of Madrigal Pharmaceuticals?
The principal executive offices are located at Four Tower Bridge 200 Barr Harbor Drive, Suite 200 West Conshohocken, Pennsylvania 19428.
What is the company's state of incorporation?
The company is incorporated in Delaware.
What former company name is listed?
The former company name listed is SYNTA PHARMACEUTICALS CORP.
Filing Stats: 1,106 words · 4 min read · ~4 pages · Grade level 13.3 · Accepted 2025-12-11 16:15:32
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 Par Value Per Share MDGL The NASDAQ Sto
- $450,000 — r will receive an annual base salary of $450,000. In addition, Ms. Thakkar will be eligi
- $1,932,000 — award with a target aggregate value of $1,932,000. Such award will be composed of: (a) 70
Filing Documents
- mdgl-20251205.htm (8-K) — 28KB
- 0001628280-25-056533.txt ( ) — 146KB
- mdgl-20251205.xsd (EX-101.SCH) — 2KB
- mdgl-20251205_lab.xml (EX-101.LAB) — 22KB
- mdgl-20251205_pre.xml (EX-101.PRE) — 13KB
- mdgl-20251205_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MADRIGAL PHARMACEUTICALS, INC. By: /s/ Mardi Dier Name: Mardi Dier Title: Executive Vice President and Chief Financial Officer Date: December 11, 2025 3